March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Hope and hype in sight: Sensationalism in choroideremia gene therapy
Author Affiliations & Notes
  • Shelly Benjaminy
    Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada
  • Tania M. Bubela
    Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada
  • Mark T. Bieber
    Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada
  • Ian M. MacDonald
    Ophthalmology, Royal Alexandra Hospital, Edmonton, Alberta, Canada
  • Footnotes
    Commercial Relationships  Shelly Benjaminy, None; Tania M. Bubela, None; Mark T. Bieber, None; Ian M. MacDonald, None
  • Footnotes
    Support  Health Quality Council of Alberta; Choroideremia Research Foundation, Canada
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 1435. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shelly Benjaminy, Tania M. Bubela, Mark T. Bieber, Ian M. MacDonald; Hope and hype in sight: Sensationalism in choroideremia gene therapy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1435.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Emerging ocular gene therapy (GT) clinical trials are raising patient hopes for a treatment for choroideremia (CHM), a degenerative retinopathy leading to blindness. GT trials raise the practical necessity of communicating risks and benefits to patients in light of a perceived ‘cure’ while avoiding the hype that has historically undermined this field of translational medicine. We hypothesize that communication about GT will be differentially interpreted by patients in the context of a potential treatment.

Methods: : We examined communications about ocular GT in two contexts: (1) word frequency analysis exploring tone of GT coverage in US, UK and Canadian newspapers (1990-2010) (nUS=5438; nUK=1522; nCA=948) using search algorithms that captured synonyms for GT in Lexis Nexis and Factiva databases; and (2) analysis of clinical communications about a CHM GT clinical trial. We conducted semi-structured interviews with 17 CHM patients and 10 clinicians responsible for their care about expected therapeutic benefits, perceived risks, and timeline of hopes for clinical implementation. We analyzed interviews using a grounded theoretical approach.

Results: : Media coverage of ocular GT described a range of outcome goals including finding a cure for CHM. Clinicians, however, emphasized that the goal of early-phase GT trials should be described in terms of a treatment rather than a cure. Patient expectations were more conservative than experts believed, centering on a hope that CHM GT will halt the progression of vision loss rather than reverse it. While clinicians believed that patients are focused on gaining access to GT rather than ensuring its safety, our analysis reveals salient patient worries about GT safety (ex. risk of accelerating vision loss). Clinicians expressed that their patients hope GT will be available sooner than experts expect, and this was confirmed by patient interviews.

Conclusions: : Our findings about patient safety concerns and conservative benefit expectations suggest that patients are well-informed and process media representations critically to avoid hype about CHM GT. Nevertheless differences between clinician understanding and patient perspectives remain. Bridging this gap will facilitate responsible communications about CHM GT and aid in the translation of this biotechnology.

Keywords: clinical (human) or epidemiologic studies: health care delivery/economics/manpower • clinical (human) or epidemiologic studies: risk factor assessment • gene transfer/gene therapy 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.